Tocilizumab in HIV patient with severe COVID-19: case report

BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition....

Descripción completa

Detalles Bibliográficos
Autores principales: Bertozzi, Pedro Vieira, de Oliveira Vicente, Amanda, Pereira, Amanda Siqueira, de Sant’Ana, Joao Pedro Espinha, Mano, Rafaela Braga Cabrera, Jorge, Luciana Souza, da Silva Sardenberg, Rodrigo Afonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520187/
https://www.ncbi.nlm.nih.gov/pubmed/34656134
http://dx.doi.org/10.1186/s12981-021-00404-5
_version_ 1784584615118241792
author Bertozzi, Pedro Vieira
de Oliveira Vicente, Amanda
Pereira, Amanda Siqueira
de Sant’Ana, Joao Pedro Espinha
Mano, Rafaela Braga Cabrera
Jorge, Luciana Souza
da Silva Sardenberg, Rodrigo Afonso
author_facet Bertozzi, Pedro Vieira
de Oliveira Vicente, Amanda
Pereira, Amanda Siqueira
de Sant’Ana, Joao Pedro Espinha
Mano, Rafaela Braga Cabrera
Jorge, Luciana Souza
da Silva Sardenberg, Rodrigo Afonso
author_sort Bertozzi, Pedro Vieira
collection PubMed
description BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient’s condition. CONCLUSION: The patient had several risk factors, such as male gender, age  >  70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient’s recovery since the drug increased his immune response, which is deficient, due to HIV infection.
format Online
Article
Text
id pubmed-8520187
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85201872021-10-18 Tocilizumab in HIV patient with severe COVID-19: case report Bertozzi, Pedro Vieira de Oliveira Vicente, Amanda Pereira, Amanda Siqueira de Sant’Ana, Joao Pedro Espinha Mano, Rafaela Braga Cabrera Jorge, Luciana Souza da Silva Sardenberg, Rodrigo Afonso AIDS Res Ther Case Report BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient’s condition. CONCLUSION: The patient had several risk factors, such as male gender, age  >  70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient’s recovery since the drug increased his immune response, which is deficient, due to HIV infection. BioMed Central 2021-10-16 /pmc/articles/PMC8520187/ /pubmed/34656134 http://dx.doi.org/10.1186/s12981-021-00404-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Bertozzi, Pedro Vieira
de Oliveira Vicente, Amanda
Pereira, Amanda Siqueira
de Sant’Ana, Joao Pedro Espinha
Mano, Rafaela Braga Cabrera
Jorge, Luciana Souza
da Silva Sardenberg, Rodrigo Afonso
Tocilizumab in HIV patient with severe COVID-19: case report
title Tocilizumab in HIV patient with severe COVID-19: case report
title_full Tocilizumab in HIV patient with severe COVID-19: case report
title_fullStr Tocilizumab in HIV patient with severe COVID-19: case report
title_full_unstemmed Tocilizumab in HIV patient with severe COVID-19: case report
title_short Tocilizumab in HIV patient with severe COVID-19: case report
title_sort tocilizumab in hiv patient with severe covid-19: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520187/
https://www.ncbi.nlm.nih.gov/pubmed/34656134
http://dx.doi.org/10.1186/s12981-021-00404-5
work_keys_str_mv AT bertozzipedrovieira tocilizumabinhivpatientwithseverecovid19casereport
AT deoliveiravicenteamanda tocilizumabinhivpatientwithseverecovid19casereport
AT pereiraamandasiqueira tocilizumabinhivpatientwithseverecovid19casereport
AT desantanajoaopedroespinha tocilizumabinhivpatientwithseverecovid19casereport
AT manorafaelabragacabrera tocilizumabinhivpatientwithseverecovid19casereport
AT jorgelucianasouza tocilizumabinhivpatientwithseverecovid19casereport
AT dasilvasardenbergrodrigoafonso tocilizumabinhivpatientwithseverecovid19casereport

Ejemplares similares